Agonists of Peroxisome-Proliferator Activated Receptor-Gamma Reduce Renal Ischemia/Reperfusion Injury
Authors:
- Prabal K. ChatterjeePCPrabal K. Chatterjee
- Nimesh S.A. PatelNPNimesh S.A. Patel
- Zoran TodorovicZoran Todorovic
- Yoshiyuki HattoriYHYoshiyuki Hattori
- Paul A.J. BrownPBPaul A.J. Brown
- Keith N. StewartKSKeith N. Stewart
- Helder Mota-FilipeHMHelder Mota-Filipe
- Salvatore CuzzocreaSCSalvatore Cuzzocrea
- Christoph ThiemermannCTChristoph Thiemermann
- 1 April 2003
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 23 (4) , 267-276
Abstract
Background/Aims: Recent evidence indicates that peroxisome-proliferator activated receptor (PPAR) agonists protect against ischemia/reperfusion (I/R) injury. Here we investigate the effects of the PPAR-γ agonists, rosiglitazone and ciglitazone, on the renal dysfunction and injury caused by I/R of the rat kidney in vivo. Methods: Rosiglitazone or ciglitazone were administered to male Wistar rats prior to and during reperfusion. Biochemical indicators of renal dysfunction and injury were measured and histological scoring of kidney sections was used to assess renal injury. Expression of PPAR isoforms and intercellular adhesion molecule-1 during renal I/R were assessed using RT-PCR and Northern blot, respectively. Myeloperoxidase activity and activation of poly(ADP-ribose) polymerase (PARP) were used as indicators of polymorphonuclear (PMN) cell infiltration and oxidative stress, respectively. Results: Expression of PPAR-α, PPAR-β and PPAR-γ1 (but not PPAR-γ2) was observed in kidneys with down-regulation of PPAR-α expression during renal I/R. Rosiglitazone and ciglitazone significantly reduced biochemical and histological signs of renal dysfunction and injury. Renal expression of ICAM-1 caused by I/R was reduced by rosiglitazone and ciglitazone which was reflected by decreased PMN infiltration into reperfused renal tissues. Both rosiglitazone and ciglitazone reduced PARP activation indicating a reduction of oxidative stress. Conclusion: These results suggest that the PPAR-γ agonists rosiglitazone and ciglitazone reduce the renal dysfunction and injury associated with I/R of the kidney. We propose that one mechanism underlying the protective effects involves inhibition of the expression of ICAM-1, a reduction of PMN infiltration into renal tissues and subsequent reduction of oxidative stress.Keywords
This publication has 11 references indexed in Scilit:
- PPARα Activator Effects on Ang II–Induced Vascular Oxidative Stress and InflammationHypertension, 2002
- Peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) activation suppresses ischemic induction of Egr‐1 and its inflammatory gene targetsThe FASEB Journal, 2002
- Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-γ ligand, pioglitazone, in ratsRedox Report, 2002
- Ligands of the peroxisome proliferator‐activated receptors (PPAR‐γ and PPAR‐α) reduce myocardial infarct sizeThe FASEB Journal, 2002
- Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal diseaseKidney International, 2001
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001
- The PPARs: From Orphan Receptors to Drug DiscoveryJournal of Medicinal Chemistry, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- The role of cell adhesion molecules in ischemic acute renal failureThe American Journal of Medicine, 1999
- Treatment of acute renal failureKidney International, 1998